2,2'-dithiobisbenzamides and 2-benzisothiazolones, two new classes of antiretroviral agents: SAR and mechanistic considerations

Drug Design and Discovery

Volumn 15, Issue 1, 1997, Pages 49-61

  Domagala, John M ^a   Gogliotti, Rocco ^a   Sanchez, Joseph P ^a   Stier, Michael A ^a   Musa, Kimberly ^a   Song, Yuntao ^a   Loo, Joseph ^a   Reily, Michael ^a   Tummino, Peter ^a   Harvey, Patricia ^a   Hupe, Donald ^a   Sharmeen, Lamia ^a   Mack, David ^a   Scholten, Jeff ^a   Saunders, James ^a   Mcquade, Thomas ^a  

^a PFIZER INC   (United States)

Author keywords

AIDS; Anti HIV disulfides; Antiretroviral; HIV; NCp7; Nucleocapsid protein

Indexed keywords

ANTIRETROVIRUS AGENT; BENZAMIDE DERIVATIVE; THIAZOLE DERIVATIVE; ZINC FINGER PROTEIN;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; DRUG MECHANISM; DRUG STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; SIMIAN IMMUNODEFICIENCY VIRUS; STRUCTURE ACTIVITY RELATION; VIRUS NUCLEOCAPSID;

ALKYLATION; ANIMALS; ANTI-HIV AGENTS; BENZAMIDES; CELL LINE; DISULFIDES; HIV-1; HUMANS; MICE; NUCLEOCAPSID PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; THIOAMIDES;

EID: 8544255533     PISSN: 10559612     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Aggleton, P., O'Reilly, K., Slutkin, G. and Davies, P. (1994). Risking everything? Risk behavior, behavior change, and AIDS, Science, 265, 341-345.
2. DeClercq, E. (1995). Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections, J Med. Chem., 38, 2491-2577.
3. Connolly, K J. and Hammer, S M. (1992). Antiretroviral therapy. strategies beyond single agent reverse transcriptase inhibition, Antimicrob. Agents Chemother, 36, 509-520.
4. Pillay, D., Bryant, M., Getman, D. and Richman, D. D. (1995). HIV-1 protease inhibitors - their development, mechanism of action and clinical potential. Medical Virol , 5, 23-33.
5. Churchill, S. A. (1996). Protease inhibitors: implications for HIV research and treatment, J. Int. Assoc. Physicians AIDS Care, January, 13-18.
6. Stone, D. (1995). HIV protease inhibitors head to market, Bia/Technology, 13, 940-942.
7. MacDougall, D. S. (1996). Saquinavir: newest weapon in the antiviral arsenal, J. Int. Assoc. Physicians AIDS Care, February, 25-31.
8. Decks, S. and Volberding, P. (1995). Combined antiretroviral therapy: the emerging role, Hospital Practice, 30(Suppl. 1), 23-31
9. Larder, B. A . Kemp, S D. and Harrigan, P. R. (1995). Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy, Science, 269, 696-699.
10. Ho, D D., Neumann, A U., Perelson, A. S., Chen, W., Leonard, J. M. and Markowitz, M. (1995). Rapid turnover of plasma virions and CD4 Iymphocytes in HIV-1 infection, Nature, 373, 123-126.
11. Mascolini, M. (1995). Paradigms, platitudes, opportunities, J. Int. Assoc. Physicians AIDS Care, November, 16-29.
12. Altman, L. K (1996) The doctor's world: new AIDS therapies arise but who can afford the bill?, New York Times, Col. 1, pg. 1, Sec. A, Tuesday, Feb. 6.
13. Yang, S. S. (1995). The NCI's AIDS antiviral drug screening program, Leukemia, October 9, (Suppl. 1), S9-11.
14. Buckheit, Jr. R. W., Hollingshead, M. G., Germany Decker, J , White, E. L., McMahon, J. B , Allen, L. B., Ross, L. R., Decker, D , Westbrook, L., Shannon, W. M., Weislow, O., Bader, J. P. and Boyd, M. R. (1993). Thiazoloben-zimidazole: biological and biochemical antiretroviral activity of a new nonnucleoside reverse transcriptase inhibitor, Antiviral Res., 21, 247-265.
15. Rice, W. G., Schaeffer, C. A., Graham, L., Bu, M., McDougal, J. S., Orioff, S. L., Villinger, M. Y., Oroszlan, S., Fesen, M. R., Pommier, Y., Mendeleyev, J. and Kun, E (1993). The site of antiviral action of the 3-nitrosobenzamides on the infectivity process of human immunodeficiency virus in human lymphocytes, Proc. Natl. Acad. Sci., 90, 9721-9724
16. Rice, W. G., Supko, J. G , Malspeis, L., Buckheit, R. W., Clanton, D., Bu, M., Graham, L., Schaeffer, C A., Turpin, J A , Domagala, J M., Gogliotti, R., Bader, J. P., Halliday, S. M., Coren, L , Sowder, R. C., Arthur, L. O. and Henderson, L. E. (1995). Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS, Science, 270, 1194-1197.
17. Tummino, P. J., Scholten, J. D., Harvey, P. J., Holler, T. P., Maloney, L., Gogliotti, R. and Domagala, J. M. (1996). The in vitro ejection of zinc from human immunodeficiency virus (HIV) type 1 nucleocapsid protein by disulfide benzamides with cellular anti HIV activity. Proc. Nat. Acad. Sci. USA, 93, 969-973.
18. Summers, M F., Henderson, L. E., Chance, M. R., Bess, J. W., South, T. L , Blake, P. R., Sagi, I., Perez-Alvarado, Sowder III, R. C , Hare, D. R. and Arthur. L. O (1992). Nucleocapsid zinc fingers detected in retroviruses: EXAFS studies of intact virus and the solution state structure of the nucleocapsid protein from HIV-1. Prot Sci., 1, 563-574.
19. DeRocquingny, H., Gabus, C., Vincent, A., Fournie-Zaluski, M. C , Roques, B and Darlix, J. L. (1992) Viral RNA annealing activities of human immunodeficiency virus type 1 nucleocapsid protein require only peptide domains outside the zinc fingers. Proc Natl. Acad. Sci. USA, 89, 6472-6476.
20. Zhang, Y. and Barklis, E. (1995). Nucleocapsid protein effects on the specificity of retrovirus RNA encapsidation, J. Virol , 69, 5716-5722
21. Gorelick, R. J., Nigida, S. M., Bess, J. W., Author, L. O., Henderson, L. E. and Rein, A. (1990). Noninfectious human immunodeficiency virus type 1 mutant deficient in genomic RNA, J. Virol., 64, 3207-3211.
22. Lapadat-Rapolsky, M., Pernelle, C., Bone, C and Darlix, J. L. (1995). Analysis of the nucleic acid annealing activities of nucleocapsid protein from HIV-1, Nucleic Acid Res., 23, 2434-2441.
23. Rodriguez-Rodriguez, L., Tsuchihashi, Z., Fuentes, G. M., Bambara, R. A and Fay, P. J. (1995). Influence of human immunodeficiency virus nucleocapsid protein on synthesis and strand transfer by the reverse transcriptase in vitro, J. Biol. Chem., 270, 15005-15011.
24. Karpel, R. L., Henderson, L. E. and Oroszlan, S. (1987). Interactions of retroviral structural proteins with single stranded nucleic acids. J. Biol. Chem., 262, 4961-4967.
25. Young, R. A. and Aldovini, A. (1990). Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus, J. Virol., 64, 1920-1926.
26. Darlix, J. L., Lapadat-Tapolski, M., DeRocquigny, H and Roques, B. P. (1995). First glimpses at structure-function relationships of the nucleocapsid protein of retroviruses. J Mol. Biol., 254, 523-537
27. Loo, J. A., Holler, T. P, Sanchez, J., Gogliotti, R., Maloney, L. and Reily, M. D. (1996) Biophysical Characterization ot Zinc ejection from HIV nucleocapsid protein by anti-HIV 2,2'-dithiobis[benzamides] and benziisothiazolones, J Med. Chem., 39, 4313-4320
28. McQuade, T., Heldsinger, A., Domagala, J., Gracheck. S and Sharmeen, L. (1996). Anti-viral activity of CI-1012 (PD 159206) and CI-1013 (PD 161374): novel anti-HIV agents which function at early steps of virus replication, Proceedings from the 3rd Conference of Retroviruses and Opportunistic Infections, January 28-February 1. Washington D.C., Abstr 341.
29. Okachi, R , Niino, H , Kitaura, K., Mineura, K., Nakamizo, Y., Murayama, Y. Ono, T. and Nakamizo. A. (1985). Synthesis and amibacterial activity of 2.2'-dithiobisbenzamide derivatives against Mycobacterium species. J Med Chem , 28, 1772-1779.